Bjerrum Jacob Tveiten, Munck Lars Kristian, Nielsen Ole Haagen
Gastroenheden, Medicinsk Sektion, Herlev Hospital, Herlev, Denmark.
Ugeskr Laeger. 2011 Aug 29;173(35):2110-3.
A systematic review to evaluate the efficacy of 5-aminosalicylates for induction of remission or clinical response in patients with mild to moderately active Crohn's disease is described. The effect of either high (3 to 4.5 g/day) or low dose (1 to 2 g/day) 5-aminosalicylic acid was similar to that of placebo. Overall, sulfasalazine was not superior to placebo and was inferior to glucocorticoids for the treatment of mild to moderately active Crohn's disease. Neither published nor unpublished data support any use of 5-aminosalicylates for the treatment of Crohn's disease.
本文描述了一项系统性综述，旨在评估5-氨基水杨酸酯类药物诱导轻度至中度活动性克罗恩病患者缓解或临床反应的疗效。高剂量（3至4.5克/天）或低剂量（1至2克/天）5-氨基水杨酸的效果与安慰剂相似。总体而言，柳氮磺胺吡啶在治疗轻度至中度活动性克罗恩病方面并不优于安慰剂，且不如糖皮质激素。已发表和未发表的数据均不支持使用5-氨基水杨酸酯类药物治疗克罗恩病。
